Skip to main content
PMC home page
Public Health Reports logoLink to Public Health Reports
. 1988 May-Jun;103(3):309–319.

Forecasting the personal medical care costs of AIDS from 1988 through 1991.

F J Hellinger 1
PMCID: PMC1478076  PMID: 2836880

Abstract

The personal medical care costs of those diagnosed with acquired immunodeficiency syndrome (AIDS) in 1988 are forecast to be $2.2 billion, an amount that will increase to $4.5 billion in 1991. This is the first study to include the cost of purchasing azidothymidine (AZT), also called zidovudine, a palliative treatment for AIDS. The forecasts of this study are lower than those reported by Rice and Scitovsky, and other researchers, because the data are more recent and AIDS patients are receiving more care on an outpatient basis and staying in the hospital fewer days. They are also lower because projections for the number of AIDS cases diagnosed in future years are lower than those made by the Centers for Disease Control (CDC). This study projects that about 38,000 AIDS cases will be diagnosed in 1988 and 73,000 in 1991. The projections in this study are derived using data on the number of AIDS cases reported to CDC from January 1984 to October 1987, while the CDC projections employed by Rice and Scitovsky were derived using data from June 1981 to May 1986. It is also projected that the lifetime cost of treating an AIDS patient will increase from $57,000 in 1988 to $61,800 in 1991 due to the wider use of AZT.

Full text

PDF
309

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrulis D. P., Beers V. S., Bentley J. D., Gage L. S. The provision and financing of medical care for AIDS patients in US public and private teaching hospitals. JAMA. 1987 Sep 11;258(10):1343–1346. [PubMed] [Google Scholar]
  2. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  3. Hardy A. M., Rauch K., Echenberg D., Morgan W. M., Curran J. W. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA. 1986 Jan 10;255(2):209–211. [PubMed] [Google Scholar]
  4. Hardy A. M., Starcher E. T., 2nd, Morgan W. M., Druker J., Kristal A., Day J. M., Kelly C., Ewing E., Curran J. W. Review of death certificates to assess completeness of AIDS case reporting. Public Health Rep. 1987 Jul-Aug;102(4):386–391. [PMC free article] [PubMed] [Google Scholar]
  5. Johnstone B. AIDS: German survey's gloomy outlook. Nature. 1986 Nov 20;324(6094):199–199. doi: 10.1038/324199c0. [DOI] [PubMed] [Google Scholar]
  6. May R. M., Anderson R. M. Transmission dynamics of HIV infection. Nature. 1987 Mar 12;326(6109):137–142. doi: 10.1038/326137a0. [DOI] [PubMed] [Google Scholar]
  7. Morgan W. M., Curran J. W. Acquired immunodeficiency syndrome: current and future trends. Public Health Rep. 1986 Sep-Oct;101(5):459–465. [PMC free article] [PubMed] [Google Scholar]
  8. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297–1302. doi: 10.1056/NEJM198711193172101. [DOI] [PubMed] [Google Scholar]
  9. Scitovsky A. A., Cline M., Lee P. R. Medical care costs of patients with AIDS in San Francisco. JAMA. 1986 Dec 12;256(22):3103–3106. [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES